| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -23,833 | -15,141 |
| Stock-based compensation | 2,143 | 1,359 |
| Impairment charge on investment in equity securities | 0 | - |
| Depreciation | 12 | 8 |
| Loss on disposal of assets | 0 | 0 |
| Prepaid materials | 1,045 | 1,377 |
| Prepaid expenses and other current assets | -585 | -90 |
| Other assets | 339 | 10 |
| Accounts payable | 2,853 | 1,331 |
| Accrued expenses | 1,070 | 1,281 |
| Payroll liabilities | -737 | -808 |
| Other current liabilities | 68 | 49 |
| Net cash used in operating activities | -19,223 | -13,218 |
| Purchases of property and equipment | 16 | 9 |
| Net cash used in investing activities | -16 | -9 |
| Proceeds from exercise of warrants | 0 | 0 |
| Net cash provided by financing activities | 0 | 0 |
| Net decrease in cash, cash equivalents and restricted cash | -19,239 | -13,227 |
| Cash and cash equivalents at beginning of period | 71,194 | - |
| Cash and cash equivalents at end of period | 51,955 | - |
ATOSSA THERAPEUTICS, INC. (ATOS)
ATOSSA THERAPEUTICS, INC. (ATOS)